CBG: The "Mother Cannabinoid" and Its Emerging Research Profile
What we know — and don't know — about cannabigerol's therapeutic potential
Cannabigerol (CBG) is the biosynthetic precursor to THC, CBD, and CBC — earning it the nickname "mother cannabinoid." It is present in low concentrations in most cannabis strains but is attracting growing research interest for its unique pharmacological profile. This article reviews the current evidence.
What Is CBG?
Cannabigerol (CBG) is a non-intoxicating phytocannabinoid found in Cannabis sativa. It is often called the "mother cannabinoid" because cannabigerolic acid (CBGA) is the biosynthetic precursor from which THCA, CBDA, and CBCA are synthesized. As cannabis matures, most CBGA is converted to these other cannabinoid acids, leaving CBG at low concentrations (<1%) in most strains. Breeders have developed high-CBG strains by harvesting early or through selective breeding.
CBG was first isolated in 1964 by Raphael Mechoulam and Yehiel Gaoni — the same year THC was first isolated. Despite this early discovery, CBG research has lagged far behind THC and CBD due to its low natural abundance and the difficulty of obtaining sufficient quantities for research.
Pharmacology: A Unique Multi-Target Profile
CBG has a distinct pharmacological profile that differs from both THC and CBD. It acts as a partial agonist at CB1 and CB2 receptors (unlike CBD, which has low affinity for both). It is also an α2-adrenoceptor agonist (potentially relevant for pain and anxiety), a 5-HT1A antagonist (contrasting with CBD's 5-HT1A agonism), a TRPA1 agonist (relevant for pain and inflammation), and an inhibitor of anandamide reuptake (raising endocannabinoid tone).
This multi-target profile gives CBG a broad potential therapeutic footprint, but also makes it challenging to study — it is difficult to attribute effects to a single mechanism.
Inflammatory Bowel Disease: The Strongest Preclinical Evidence
The most compelling preclinical evidence for CBG is in inflammatory bowel disease. A 2013 study by Borrelli et al. found that CBG significantly reduced colon weight, macroscopic damage, myeloperoxidase activity, and pro-inflammatory cytokines (IL-1β, IL-10, IFN-γ) in a murine colitis model. The authors proposed CBG as a candidate for clinical trials in IBD.
Subsequent preclinical studies have confirmed anti-inflammatory effects in colitis models. The mechanism likely involves CB2 receptor activation on intestinal immune cells, TRPA1 modulation, and direct anti-inflammatory effects on intestinal epithelial cells. No completed human clinical trials for CBG in IBD have been published as of mid-2026.
Antibacterial Activity: MRSA and Beyond
A 2008 study by Appendino et al. found that CBG (along with CBD, CBC, CBN, and THC) had potent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) — a major antibiotic-resistant pathogen. CBG showed minimum inhibitory concentrations (MICs) comparable to vancomycin, the gold-standard MRSA treatment.
Subsequent research has confirmed CBG's antibacterial activity against multiple drug-resistant organisms. The mechanism appears to involve disruption of bacterial cell membranes. While these findings are intriguing, translating in vitro antibacterial activity to clinical use requires demonstrating efficacy in animal infection models and ultimately in human trials — steps that have not yet been completed for CBG.
Neuroprotection and Neurodegeneration
Preclinical studies suggest CBG may have neuroprotective properties relevant to neurodegenerative diseases. A 2015 study by Valdeolivas et al. found that CBG was neuroprotective in a mouse model of Huntington's disease, reducing striatal neuronal loss and improving motor deficits. CBG also showed neuroprotective effects in models of Parkinson's disease and ALS.
The mechanisms proposed include antioxidant activity, anti-neuroinflammatory effects via CB2 receptors, and PPAR-γ activation. As with other preclinical cannabinoid findings, the translation to human clinical benefit remains to be demonstrated.
Current Research Status and Outlook
CBG research is in early stages. The evidence base consists almost entirely of preclinical studies (cell culture and animal models). No Phase II or III clinical trials for CBG have been completed. The growing commercial interest in CBG has outpaced the science — CBG products are widely marketed for conditions (anxiety, pain, sleep) with minimal clinical evidence.
The most promising near-term research directions are IBD (where preclinical evidence is strongest and there is significant unmet need) and antibacterial applications. As high-CBG strains become more available and extraction technology improves, the supply constraints that have limited CBG research are easing. Expect more clinical trial data in the next 3–5 years.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making treatment decisions. See our editorial standards.